Antion Biosciences announces development of safety-enhanced and off-the-shelf CAR T-cells for autoimmune disease Aiming for a best-in-class solution to treat and cure B-cell driven autoimmune diseases

Antion Biosciences announces latest data and validation of its technology platform through important milestone achievements Antion Biosciences release in vivo proof-of-concept data for miCAR7 and milestone achievement for Allogene Therapeutics

Antion Biosciences Announces Presentation of Two Abstracts from its Multiplex Cell Engineering Platform at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting Functional demonstration of Antion’s uniquely capable technology to develop allogeneic anti-CD19 CAR T-cells with “tuned” silencing of HLA-I Latest advancements in the application of Antion’s miCAR...

Antion Announces Granting of Key Technology Patent in the United States GENEVA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Antion Biosciences SA (Antion), an innovative developer of cell and gene therapy technologies, is pleased to announce the granting of a significant patent...

Antion Welcomes John Tchelingerian as Chairman of the Board GENEVA, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Antion Biosciences SA (Antion) proudly announces the appointment of John Tchelingerian, PhD, a veteran of the biotech industry, as the new Chairman of its...